// App-Quantinova.ai

317TiP : IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)

Researchers

Presenter

  • D.Miles

Principal Investigators

  • F.Andre

  • J.Gligorov

  • S.Verma

  • D.Cameron

  • C.H.Barrios

  • A.Schneeweiss

  • V.Easton

  • I.Dolado

  • J.O'Shaughnessy

Medical Centers

  • Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK

  • Dpt of Medical Oncology, Gustave Roussy, Villejuif, France

  • Medical Oncology, Institut Universitaire de Cancérologie, IUC-UPMC, Sorbonne Univeristy, Paris, France

  • Oncology, Cumming School of Medicine, University of Calgary Alberta Health Services, Calgary, AB, Canada

  • National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

  • MRC Institute of Genetics & Molecular Medicine, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK

  • Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil

  • Division Gynecologic Oncology, National Center for Tumor Diseases (NTC) University Hospital, Heidelberg, Germany

  • PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • PD Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • Texas Oncology-Baylor University Medical Center-US Oncology Research, Dallas, TX

Locations

  • United Kingdom

  • France

  • Canada

  • China

  • Brazil

  • Germany

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Paclitaxel

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved